InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,509.01
(
0.62%
)
US TECH 100
19,452.80
(
0.91%
)
Dow Jones
39,331.85
(
0.41%
)
Brent Oil
86.34
(
-0.23%
)
Bitcoin
61,792.07
(
-1.68%
)
Post# of 252464
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119970
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: bladerunner1717 post# 150574

Monday, 10/15/2012 1:26:04 PM

Monday, October 15, 2012 1:26:04 PM

Post# of 252464
ABT’s HCV results in the null-responder population are off-the-charts superlative; the age of interferon use in HCV may truly be nearing an end. Moreover, ABT did it without using a nuke in the cocktail.

Detailed discussion of these results will have to wait for the PR/presentation at AASLD, but it appears that ABT’s prior boasting of “unprecedented” success in HCV (#msg-68216224) was not unfounded.

p.s. ABT is trading today at an all-time high.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up